Attune Pharmaceuticals
Edit

Attune Pharmaceuticals

http://attunepharma.com/
Last activity: 24.01.2019
Active
Categories: BioTechDrugInvestmentMedtech
Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel oral once-daily small-molecule therapeutics for the treatment of rare diseases.
Mentions
7
Total raised: $23M

Investors 2

Funding Rounds 1

DateSeriesAmountInvestors
24.01.2019Series B$23M-

Mentions in press and media 7

DateTitleDescription
24.01.2019Attune Pharmaceuticals Secures $23M NEW YORK, NY, Attune Pharmaceuticals today announced the completion of a $23 million Series B financing. >> Click here for more funding data on Attune Pharmaceuticals >> To export Attune Pharmaceuticals funding data to PDF a...
24.01.2019Attune Pharmaceuticals Closed $23M Series B FinancingAttune Pharmaceuticals, Inc., a NYC-based biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics for the treatment of rare diseases, closed a $23m Series B financing. The ro...
23.01.2019Term Sheet — Wednesday, January 23CRYPTO CAPITAL Good morning, Term Sheet readers. Paid Content A.I. is the answer to protecting your enterprise in the cloud From ExtraHop Here’s the quick rundown: • Symbiont, a blockchain platform that caters to financial institutions, ann...
23.01.2019Attune Pharmaceuticals Announces $23M Series B FinancingNEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Attune Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics for the treatment of rare diseases, today ...
23.01.2019Attune Pharmaceuticals bags $23M for oral HAE drugAttune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema (HAE) through phase 2. The biotech aims to provide an oral alternative to approved treatments, all of which are either intraveno...
23.01.2019Attune Pharmaceuticals bags $23M for oral HAE drugAttune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema (HAE) through phase 2. The biotech aims to provide an oral alternative to approved treatments, all of which are either intraveno...
23.01.2019Daily funding roundup - January 23nd, 2019AnChain.ai raised $2M; Chowbus raised $4M; Groww aised $6.2M; Anchorage raised $17 AnChain.ai: AnChain.ai is an AI powered blockchain ecosystem security. AnChain.ai has raised $2 million in seed funding led by AMINO Capital, with participat...

Reviews 0

Sign up to leave a review

Sign up Log In